See every side of every news story
Published loading...Updated

Biotronik nets short DAPT and calcified lesion indications for Orsiro Mission DES - Cardiovascular News

Summary by Cardiovascular News
Biotronik has announced CE mark approval of two new indications for the Orsiro Mission drug-eluting stent (DES). These include one-month dual antiplatelet therapy (DAPT) for high bleeding risk (HBR) patients, allowing practitioners to offer personalised, shorter DAPT durations to their patients at high risk of bleeding events, in accordance with the most recent guidelines. Additionally, the Orsiro Mission DES has been approved for calcified lesi…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Cardiovascular News broke the news in on Tuesday, January 14, 2025.
Sources are mostly out of (0)

Similar News Topics